Login to Your Account

Synairgen breathes easier with $225M from Astrazeneca for its asthma drug

By Nuala Moran
Staff Writer

Thursday, June 12, 2014

After two years of discussions, Synairgen plc has landed Astrazeneca plc as partner for its asthma treatment SNG001 in a $225 million deal. Astrazeneca will pay $7.25 million up front and now takes over development of SNG001, an inhaled formulation of interferon beta.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription